ArticleThe Journal of infectious diseases2020
Estimating Global Epidemiology of Low-Pathogenic Human Coronaviruses in Relation to the COVID-19 Context.
Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Cross-Reactive IgG Antibody Responses to SARS-CoV-2 in Older Adults Following Seasonal Coronavirus Infection in Jiangsu, China (2015-2017).Influenza and other respiratory viruses · 2026Article
- Global Epidemiology and Seasonality of Human Seasonal Coronaviruses: A Systematic Review.Open forum infectious diseases · 2024Article
- Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response.iScience · 2023Article
- Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies.Pathogens (Basel, Switzerland) · 2023Review
- The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.Nature reviews. Immunology · 2023Review
- Broad antiviral and anti-inflammatory efficacy of nafamostat against SARS-CoV-2 and seasonal coronaviruses in primary human bronchiolar epithelia.Nano select : open access · 2022Article
- Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.Scientific reports · 2021Article
- Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses.Virology · 2021Article
- Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study.Microorganisms · 2021Review
- Systematically comparing COVID-19 with the 2009 influenza pandemic for hospitalized patients.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?Trends in immunology · 2020Article
Corrections and comments
- Commented on by
- Comment on
- Comment on
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.